Prima BioMed is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders.
Prima's main pipeline of products is based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. The most clinically advanced product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.
Pharmaceuticals and Medicine Manufacturing
The Drugs and Medicine industry involves research, development, manufacturing and distribution of pharmaceutical drugs and medicines. Companies in this field focus on preventing and treating illness using medicinal compounds and therapies.
Career Opportunities at Immutep Ltd.
Stay updated on the latest job openings by checking back regularly or by visiting the company's official career page.
No job listings currently found.
Employees of 'Immutep Ltd.'
Decision makers at Immutep
15 Decision Makers at Immutep
Purchasing & operations at Immutep
22 Purchasing & Operations at Immutep
Marketing & media at Immutep
2 Marketing & Media at Immutep
Information technology at Immutep
4 Information Technology at Immutep
Details of Immutep
Related Companies and Competitors
Access All Contact Details
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive to ensure that the information is accurate and up-to-date, we cannot guarantee its completeness or accuracy. We do not endorse or guarantee the products or services of any company or individual listed.
